Colorectal cancer epigenetics: The role of environmental factors and the search for molecular biomarkers

Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews

Volumn 25, Issue 2, 2007, Pages 101-154

  Ahmed, Farid E ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Aging; Chromosome Inactivation; CpG; Gene Silencing; Imprinting; MSI; Nutrition; Polymorphism; Pyrosequencing; Therapy

Indexed keywords

DISEASE CONTROL; DNA; ENVIRONMENTAL IMPACT ASSESSMENTS; METHYLATION; TUMORS;

CANCER EPIGENETICS; CARCINOGENESIS; MOLECULAR BIOMARKERS;

BIOMARKERS;

FLUOROURACIL; MOLECULAR MARKER;

CANCER RISK; CARCINOGENESIS; CHROMATIN STRUCTURE; COLORECTAL CANCER; DIET; DNA METHYLATION; DNA MODIFICATION; DNA TRANSCRIPTION; ENVIRONMENTAL FACTOR; EPIGENETICS; EVALUATION; GENE EXPRESSION; GENETIC DISORDER; GENETIC DRIFT; GENOME; HUMAN; LEARNING; MUTATION; NONHUMAN; PROGNOSIS; REVIEW; RISK ASSESSMENT; SCREENING; SENSITIVITY AND SPECIFICITY; STOCHASTIC MODEL; TREATMENT PLANNING; VALIDATION STUDY; X CHROMOSOME INACTIVATION;

ANIMALS; COLORECTAL NEOPLASMS; DNA METHYLATION; ENVIRONMENTAL POLLUTANTS; EPIGENESIS, GENETIC; HUMANS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 34250184450     PISSN: 10590501     EISSN: 15324095     Source Type: Journal    
DOI: 10.1080/10590500701399184     Document Type: Review

References (243)

1. Waddington C. The Epigenotype. Endeavor 1942;1:18-20.
2. Cottrell SE. Molecular diagnostic applications of DNA methylation technology. Clin. Biochem. 2004;37:595-604.
3. Jaenisch R, Bird A. Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat. Genet. 2003;33(Suppl):245-254.
4. Ohlsson R, Kanduri C, Whitehead J, Pfeifer S, Lobanenkov, V, Feinberg AP. Epigenetic variability and the evolution of human cancer. Adv. Cancer Res. 2003;88:145-168.
5. Bird A. DNA methylation patterns and epigenetic memery. Cancer Develop. 2002;16:6-21.
6. Murrell A. From genome to epigenome. Hum. Mol. Genet. 2005;14:R3-R10.
7. Struhl K. Fundamentally different logic of gene regulation in eukaryotes and prokaryotes. Cell 1999;98:1-4.
8. Ohlsson R, Paldi A, Graves JM. Did genomic imprinting and X inactivation arise from stochastic expression? Tr. Genet. 2001;17:136-141.
9. Baylin S, Esteller M, Roundtree M, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 2001;10:687-692.
10. Feinberg AP, Cui H, Ohlsson R. DNA methylation and genomic imprinting: Insight from cancer into epigenetic mechanisms. Semin. Cancer Biol. 2002;12:389-398.
11. Van den Veyver I. Genetic effects on methylation diets. Ann. Rev. Nutr. 2002;22:255-282.
12. Ahmed FE. Gene-gene, gene-environment & multiple interactions in colorectal cancer. J. Environ. Sci. Health C. 2006;24:1-101.
13. Gould S. Tempo and mode in the macroevolutionary reconstruction of Darwinism. Proc. Natl. Acad. Sci. USA 1994;91:6764-6771.
14. Esteller M. The necessity of a human epigenome project. Carcinogenesis 2006;27:1121-1125.
15. Kondo Y, Issa JP. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 2004;23:29-39.
16. Yoo CB, Jones PA. Epigenetic therapy of cancer: Past, present and future. Nature Rev. 2006;5:37-50.
17. Bird AP, Wolffe AP. Methylation-induced repression -belts, braces, and chromatin. Cell. 1999;99:451-454.
18. Feinbery AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983;301:89-92.
19. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylation phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA 1999;96:8681-8686.
20. Esteller M, Almouzni G. How epigenetics interates nuclear functions. EMBO Rep. 2005;6:624-628.
21. Yamashita K, Dai T, Day I, et al. Genetics supercedes epigenetics in colon cancer phenotype. Cancer Cell 2003;4:121-131.
22. Frigola J, Sole X, Paz MF, et al. Different DNA hypermethylation and hypomethylation signatures in colorectal cancer. Hum. Mol. Genet. 2005;14:319-326.
23. Anacleto C, Leopoldino AM, Rossi B, et al. Colorectal cancer "methylator phenotype": Fact or artifact? Neoplasia. 2005;7:331-335.
24. Weisenberger DT, Siegmund KD, Campan M, et al. CpG island metylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 2006;38:787-793.
25. Schuebel K, Chen W, Baylin SB. CIMPLe origin for promoter hypermethylation in colorectal cancer. Nat. Genet. 2006;38:738-740.
26. Bernestein BE, Mikkelsen TP, Xie X, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 2006;125:315-326.
27. Vire E, Brenner C, Deplus R, Blanchon L, et al. The polycomb group protein EZH2 directly controls DNA methylation. Nature 2006;439:871-874.
28. Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005;129:837-845.
29. Ward RL, Cheong K, Ku SL, et al. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite stability. J. Clin. Oncol. 2003;21:3729-3736.
30. Van Rinjnsoever M, Elsaleh H, Joseph D, et al. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin. Cancer Res. 2003;9:2898-2903.
31. Ogino S, Brahmandam M, Kawasaki T, et al. Epigenetic profiling of synchronous colorectal neoplasia by quantitative DNA methylation analysis. Modern. Pathol. 2006;19:1083-1090.
32. Ogino S, Cantor M, Kawasaki T, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterized by quantitative DNA methylation analysis and prospective cohort studies. Gut. 2006;55:1000-1006.
33. Nuovo GJ, Nakagawa H, Sotamma K, et al. Hypermethylation of the MLH1 promoter with concomitant absence of transcript and protein occurs in small patches of crypt cells in unaffected mucosa from sporadic colorectal carcinoma. Diag. Mol. Pathol. 2006;45:17-23.
34. Hatada I, Fukasawa M, Kimura M, et al. Genome-wide profiling of promoter methylation in human. Oncogene 2006;25:3059-3064.
35. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J. Natl. Cancer Inst. 2005;97:1380-1388.
36. Giovannucci E, Ogino S. DNA methylation, field effects, and colorectal cancer. J. Natl. Cancer Inst. 2005;97:1317-1319.
37. Issa JPJ. Aging, DNA methylation, and cancer. Crit. Rev. Oncol. Hematol. 1999;32:31-43.
38. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat. Genet. 1999;21:163-167.
39. Esteller M. Aberrant DNA methylation as a cancer inducing mechanism. Annu. Rev. Pharmacol. 2005;458:629-656.
40. Esteller M. Epigenetics provide a new generation of oncogenes and tumor-suppressor genes. Br. J. Cancer 2006;94:179-183.
41. Toyota M, Issa JP. CpG island methylation phenotypes in aging and cancer. Semin. Cancer Biol. 1999;9:349-357.
42. Kawakami K, Ruzkiewicz A, Bennett G, et al. DNA methylation in the normal colonic mucosa of patients with colorectal cancer. Br. J. Cancer 2006;94:593-598.
43. Iacopetta B, Grieu F, Li W, et al. APC gene methylation is inversely correlated with features of the CpG island methylation phenotype in colorectal cancer. Int. J. Cancer 2006;119:2272-2278.
44. Takahashi T, Shigematsu H, Shivapurkar N, et al. Aberrant methylation of multiple genes during multistep pathogenesis of colorectal cancer. Int. J. Cancer 2006;118:924-931.
45. Aguilera O, Fraga MF, Ballestar E, et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene. 2006;25:4116-4121.
46. Han QF, Zhao W, Bentel J, et al. Expression of sFRP-4 and β-catenin in human colorectal carcinoma. Cancer Lett. 2006;231:129-137.
47. Goel A, Arnold CN, Tassone P, et al. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancer. Int. J. Cancer 2004;112:754-759.
48. Ionov Y, Matsui SI, Cowell JK. A role for p300/CREB binding protein genes in promoting cancer progression in colon cancer cell lines with microsatellite instability. Proc. Natl. Acad. Sci. USA 2004;101:1273-1276.
49. Lee S, Hwang KS, Lee HJ, et al. Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab. Invest. 2004;84:884-893.
50. Li H, Myeroff L, Smiraglia D, et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon cancer aberrant crypt foci and cancers. Proc. Natl. Acad. Sci. USA 2003;100:8412-8417.
51. Toyota M, Sasaki Y, Satoh A, et al. Epigenetic inactivation of CHFR in human tumors. Proc. Natl. Acad. Sci. USA 2003;100:7818-7823.
52. Obata T, Toyota M, Satoh A, et al. Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer. Clin. Cancer Res. 2003;9:6410-6418.
53. Hibi K, Nakayama H, Kanyama Y, et al. Methylation patterns of HLTF gene in digestive tract cancer. Int. J. Cancer 2003;104:433-436.
54. Akiyama Y, Watkins N, Suzuki H, et al. GATA-4 and GATA-5 transcription factor genes and potential down stream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol. Cell. Biol. 2003;23:8429-8439.
55. Deng G, Nguyen A, Tanaka H, et al. Regional hypermethylation and global hypomethylation are associated with altered chromatin conformation and histone acetylation in colorectal cancer. Int. J. Cancer 2006;118:2999-3005.
56. Frigola J, Song J, Stirzaker C, et al. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosomal band. Nat. Genet. 2006;38:450-549.
57. Grady WM. Epigenetic events in the colorectum and in colon cancer. Biochem. Soc. Transact. 2005;33:684-688.
58. Guleng G, Løvig T, Meling GT, et al. Mitochondrial microsatellite instability in colorectal carcinoma - frequency and association with nuclear microsatellite instability. Cancer Lett. 2005;219:97-103.
59. Lofton-Day C, Lesche R. DNA methylation markers in patients with gastrointestinal cancer. Dig. Dis. 2003;21:299-308.
60. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N. Eng. J. Med. 2003;349:2042-2054.
61. Feinberg AR, Tycko B. Timeline: The history of cancer epigenetics. Nat. Rev. Cancer 2004;4:1-11.
62. Reik W, Walter J. Genomic imprinting: Parental influence on the genome. Nat. Rev. Genet. 2001;2:21-32.
63. McGrath J, Solter D. Completion of mouse embryogenesis requires both the maternal and paternal genomes. Cell 1984;37:179-183.
64. Surani MA, Barton SC, Norris ML. Development of reconstituted mouse eggs suggests imprinting of the genome during gametogenesis. Nature 1984;308:548-550.
65. Mutter GL. Role of imprinting in abnormal human development. Mutat Res. 1997;396:141-147.
66. DeChiara TM, Robertson EJ, Efstratiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 1991;64:849-859.
67. Murphy SK, Jirtle RL. Imprinting evolution and the price of silence. Bioessays 2003;25:577-588.
68. Killian JK, Byrd JC, Jirtle JV, et al. M6P/IGF2R imprinting evolution in mammals. Mol. Cell. 2000;5:707-716.
69. Moore T, Haig D. Genomic imprinting in mammalian development: A parental tug-of-war. Tr. Genet. 1991;7:45-49.
70. Haig D, Graham C. Genomic imprinting and the strange case of the insulin-like growth factor II receptor. Cell. 1991;64:1045-1046.
71. Falls JG, Pulford DJ, Wylie AA, Jirtle RL. Genomic imprinting: Implications for human disease. Am. J. Pathol. 1999;154:635-647.
72. Cui H, Onyango P, Brandenburg S, et al. Loss of imprinting in CRC linked to hypomethylation of H19 and IGF2. Cancer Res. 2002;62:6442-6446.
73. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: A potential marker of CRC risk. Science 2003;299:1753-1755.
74. Cruz-Correa M, Cui H, Giardiello FM, et al. Loss of Insulin Growth Factor-II gene: A potential heritable biomarker of colon neoplasia predisposition. Gastroenterology 2004;126:964-970.
75. Waterland RA, Jirtle RL. Transposable elements: Targets for early nutritional effects on epigenetic gene regulation. Mol. Cell. Bol. 2003;23:5293-5300.
76. Wylie AA, Murphy SK, Orton TC, Jirtle RL. Novel imprinted DLK1/GTL2 domain on human chromosome 14 contains motifs that mimic those implicated in IGF2/H19 regulation. Genome. Res. 2000;10:1711-1718.
77. Jirtle RL. IGF2 loss of imprinting: A potential heritable risk factor for colon cancer. Gastroenterology 2004;126:1190-1201.
78. Killian JK, Nolan CM, Wylie AA, et al. Divergent evolution in M6P/IGF2R imprinting from the Jurassic to the Quaternary. Hum. Mol. Genet. 2003;10:1721-1728.
79. Zhao R, Berho M, Nogueras J, et al. Positive correlation of insulin-like growth factor II with proliferating cell index in patients with colorectal neoplasia. Cancer Epidemiol. Biomark. Prev. 2005;14:1819-1822.
80. Kurukuti S, Tiwari VK, Tavoosidana G, et al. CTCF binding at the H19 imprinting control region mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to Igf2. Proc. Natl. Acad. Sci. USA 2006;103:10684-10689.
81. Pantoja C, de los Ríos L, Mathen A, et al. Inactivation of imprinted genes induced by cellular stress and tumorigenesis. Cancer Res. 2005;65:26-33.
82. Volpe TA, Kidner C, Hall IR, et al. Regulation of heterocromatic silencing and histone H3 lysine-9 methylation y RNAi. Science 2002;297:1833-1837.
83. Zilberman D, Cao X, Jacobsen SE. ARGONAUTE4 control of locus-specific siRNA accumulation and DNA and histone methylation. Science 2003;299:716-719.
84. Rougeulle C, Heard E. Antisense RNA in imprinting: Spreading silence through Air. Tr. Genet. 2002;18:434-437.
85. Panning B, Jaenisch R. RNA and the epigenetic regulation of X chromosome inactivation. Cell. 1998;93:305-308.
86. Tufarelli C, Stanley JA, Garrick D, et al. Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. Nat. Genet. 2003;34:157-165.
87. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-463.
88. McClintock B. Chromosome organization and gene expression. Cold Spring Harb. Symp. Quant. Biol. 1951;16:33-47.
89. Fransz P, SoppeW, Schubert I. Heterochromatin in interphase nuclei of Arabidopsis thaliana. Chromosome Res. 2003;13:227-240.
90. Sarot E, Payne-Groschene G, Bucheton A, Pelisson A. Evidence for a piwidependent DNA silencing of the gypsi endogenous retrovirus by Drosophila melanogaster flamenco gene. Genetics 2004;166:1313-1321.
91. Son X, Le HD, Wahlstrom JM, Karpen GH. Sequence analysis of a functional Drosophila centromere. Genome Res. 2003;13:182-191.
92. Lippman Z, Martienssen R. The role of RNA interference in heterocromatin silencing. Nature 2004;431:364-370.
93. Kawasaki H, Taira K. Induction of DNA methylation and gene silencing by short interfering RNAs in tumor cells. Nature 2004;431:211-216.
94. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferase Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99:247-257.
95. Amir RE, Van den Veyver IB, Wan M, et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999;23:185-188.
96. Chen WG, Chang Q, Lin Y, et al. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 2003;302:885-889.
97. Suter CM, Martin DI, Ward RL. Germline epimutation of MLH1 in individuals with multiple cancers. Nat. Genet. (doi:10.1038/ng1342), 2004.
98. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002;3:415-428.
99. Hake SB, Xiao A, Allis CD. Linking the epigenetic "language" of covalent histone modifications to cancer. Br. J. Cancer 2004;90:761-769.
100. Roberts CW, Orkin SH. The SWI/SNF complex -chromatin and cancer. Nat. Rev. Cancer 2004;133-142.
101. Richadson BC. Role of DNA methylation in the regulation of cell function: Autoimmunity, aging and cancer. J. Nutr. 2002;132:2401S-2405S.
102. Issa JP. CpG island methylation in aging and cancer. Curr. Top. Microbiol. Immunol. 2000;249:101-118.
103. Beaudet AI, Jiang YH. A rheostat model for a rapid and reversible form of imprinting-dependent evolution. Am. J. Hum. Genet. 2002;70:1389-1397.
104. Laird PW, Jackson-Grusby L, Fazeli A, et al. Suppression on intestinal neoplasia by DNA hypomethylation. Cell 1995;81:197-205.
105. Li S, Hursting SD, Davis BJ, et al. Environmental exposure, DNA methylation, and gene regulation. Ann. NY Acad. Sci. 2003;983:161-169.
106. Sheldon CC, Rouse DI, Finnegan EJ, et al. The molecular basis of vernalization: The central role of FLOWERING LOCUS C. FLC. Proc. Natl. Acas. Sci. USA 2000;97:3753-3758.
107. Gendall AR, Levy YY, Wilson A, Dean C. The VERNALIZATION 2 gene mediates the epigenetic regulation of vernalization in Arabidopsis. Cell. 2001;107:525-535.
108. Brock HW, Lohuizen M. The Polycomb group -no longer an exclusive dub? Curr. Opin. Genet. Dev. 2001;11:175-181.
109. Wilson VL, Jones PA. DNA methylation decreases in aging but not in immortal cells. Science 1983;220:1055-1057.
110. Wilson VL, Smith RA, Ma S, Cutler RG. Genomic 5-methyldeoxycytidine decreases with age. J. Biol. Chem. 1987;262:9948-9951.
111. Bestor TH, Tycko B. Creation of genomic methylation patterns. Nat. Genet. 1996;12:363-367.
112. Hertz R. The estrogen-cancer hypothesis. Cancer 1976;38:534-540.
113. Ahmed FE. Safety standards for environmental contaminants. In: C Moffat & KJ Whittle. eds. Environmental Contaminants in Food. 1999; (pp. 146-214) London, UK: Shiffield Academic Press.
114. Wagner JD, Anthony MS, Cline JM. Soy phtoestrogens: Research on benefits and risks. Clin. Obstet. Gynecol. 2001;44:843-852.
115. Millar SE, Miller MW, Stevens ME, Barsn GS. Expression and transgenic studies of the mouse agouti gene provide insight into the mechanisms by which mammalian coat color patterns are generated. Development 1995;121:3223-3232.
116. Wolff GL, Kodell RL, Moore SR, et al. Maternal epigenetics and methyl supplements affect agouti gene expression in Avyla mice. FASEB J. 1998;12:949-957.
117. Cooney CA, Dave AA, Wolff GL. Maternal methyl supplements in mice epigenetic variation and DNA methylation of offspring. J. Nutr. 2002;132:2393S-2400S.
118. Morgan HD, Sutherland HE, Martin DIK, Whitelaw E. Epigenetic inheritance at the agouti locus in the mouse. Nat Genet 1999;23:314-318.
119. Davis CD, Uthus EO. DNA methylation, cancer susceptibility, and nutrient interaction. Exp. Biol. Med. 2004;229:988-995.
120. Zhu M, Wang Y, Ai N, et al. Tea polyphenol(-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003;63:6573-6570.
121. Friso S, Choi SW. Gene-nutrient interactions in one-carbon metabolism. Cancer Drug. Metab. 2005;60:37-46.
122. Choi SW, Friso S, Ghandour H, et al. Vitamin B12 deficiency induces anomalies of base substitution and methylation in the DNA of rat colonic epithelium. J. Nutr. 2004;134:750-755.
123. Bielawski DM, Zaher FM, Svinarich DM, Abel EL. Paternal alcohol exposure affects sperm cytosine methyltransferase messenger RNA levels. Alcohol. Clin. Exp. Res. 2002;26:347-351.
124. Chia VM, Newcomb PA, Bigler J, et al. Risk of microsatellite-unstable colorectal cancer is associated jointly with smoking and nonsteroidal anti-inflammatory drug use. Cancer Res. 2006;66:6877-6833.
125. Kim YI. Folate, colorectal carcinogenesis, and DNA methylation: Lessons from animal studies. Env. Mol. Mutagen. 2004;44:10-25.
126. Giovannuci E, Stampfer MJ, Golditz GA, et al. Multivitamin use, folate and colon cancer in women in the Nurses' Health Study. Ann. Intern. Med. 1998;129:517-524.
127. Goel A, Li Ms, Nagasaki T, et al. Association of JC virus T-antigen expression with the methylator phenotype in sporadic colorectal cancer. Gastroenterology 2006;130:1850-1961.
128. Siegmund KD, Laird PW. Analysis of complex methylation data. Methods. 2002;27:170-178.
129. Model F, Adorjan P, Olek A, Piepenbrock C. Feature selection for DNA methylation based cancer classification. Bioinformatics 2001;17:S157-S164.
130. Levenson VV. DNA methylation biomarkers of cancer: Moving toward clinical application. Pharmacogenomics 2004;5:699-707.
131. Ahmed FE, Vos P, iJames S, et al. Transcriptomic molecular markers for screening human colorectal cancer in stool and tissue. Cancer Genom. Proteom. 2007;4:1-20.
132. Ahmed FE. Expression microarray proteomics and the search for cancer biomarkers. Curr. Genomics. 2006;7:399-426.
133. Ahmed FE. Laser microdissection: Application to carcinogenesis. Cancer Genom. Proteom. 2006;3:217-226.
134. Laird PW. Oncogenic mechanisms mediated by DNA methylation. Mol. Med. Today 1997;3:223-229.
135. Nakagawa H, Nuovo GJ, Zervos EE, et al. Age-related hypermethylation of the 5′ region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res. 2001;61:6991-6995.
136. Ahmed FE. qRT-PCR: Application to carcinogenesis. Cancer Genom. Proteom. 2005;2:317-332.
137. Laird PW. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 2003;3:253-266.
138. Cottrell S, Laird PW. Sensitive detection of DNA methylation. Ann. NY Acad. Sci. 2003;983:102-130.
139. Fraga MF, Esteller M. DNA methylation: A profile of methods and applications. BioTechniques 2002;33:632-649.
140. Pomrat K, Aziz K, Wu G. Screening for colorectal cancer. In K Aziz, G Wu. eds. Cancer Screening: A Practical Guide for Physicians (pp. 87-109). Totowa, NJ: Humana Press, 2002.
141. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225-3229.
142. Adorjan P, Distler J, Lipscher E, et al. Tumor class prediction and discovery by microarray-based DNA methylation analysis. Nucleic. Acids. Res. 2002;30:E21.
143. Müller HM, Oberwalder M, Fiegl H, et al. Methylation changes in faecal DNA: A marker for colorectal cancer screening? Lancet. 2004;363:1283-1285.
144. Sullivan M, Pepe S, Etzioni R, et al. Phase of biomarker development for early detection, J. Natl. Cancer Inst. 2001;93:1054-1061.
145. Burtis CA, Ashwood ER eds. Tietz Textbook of Clinical Chemistry. 1994; Philadelphia: W B Sanders Company.
146. Hainley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristics. ROC curve. Radiology 1982;143:29-36.
147. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: Quantifications and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;81:1659-1665.
148. Shanmugathasan M, Jothy S. Apoptosis, anoikis and their relevance to the pathobiology of colon cancer. Pathol. Int. 2000;50:273-279.
149. Chen WD, Hanz J, Skoletsky J, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J. Natl. Cancer Inst. 2005;97:1124-1132.
150. Lenhard K, Bommer GT, Asutay S, et al. Analysis of promoter methylation in stool: A novel method for the detection of colorectal cancer. Clin. Gastroenterol Hepatol. 2005;3:142-149.
151. Belshaw NJ, Elliott GO, Williams EA, et al. Use of DNA from human stool to detect aberrant CpG island methylation of genes implicated in colorectal cancer. Cancer Epidemiol. Biomark Prev. 2004;13:1495-1501.
152. Ptko Z, Ghiassi M, Shuber A, et al. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin. Cancer Res. 2005;11:1203-1209.
153. Loktionov A, O'Neil IK, Silvester KP, et al. Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer. Clin. Cancer Res. 1998;4:337-342.
154. Ahlquist DA. Morphometric analysis of the "mucocellular layer" overlying colorectal cancer and normal mucosa: Relevance to exfoliation and stool screening. Hum Pathol 2000;31:51-57.
155. Nair P, Lagerholm S, Dutta S, et al. On the nature of cellular elements from stool in the pathophysiology of colonic disease. J. Clin. Gastroenterol 2003;36(Suppl 1):584-591.
156. Quirke P, Dixon MF, Clayden AD, Durdey P, Dyson JE, Williams NS, Bird CC. Prognostic significance of DNA aneuploidy and cell proliferation in rectal adenocarcinomas. J. Pathol. 1987;151:285-291.
157. Jubb AM, Quirke P, Oates AJ. DNA methylation, a biomarker for colorectal cancer. Ann. NY Acad. Sci. 2003;9830:251-267.
158. Lecomte T, Berger A, Zinzindohoue F, et al. Detection of the free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int. J. Cancer 2002;100:542-548.
159. Ahmed FE. Colon cancer: Molecular staging models that characterize risk and enhance prgnosis. Cancer Genom. Proteo. 2004;1:295-310.
160. Issa JPJ. Methylation and prognosis of molecular clocks and hypermethylator phenotypes. Clin. Cancer Res. 2003;9:2879-2881.
161. Crawford JM. The gastrointestinal tract. In RS Cotran, V Kumar, T Collins. eds. Robbins Pathologic Basis of Disease (pp. 775-843). 1999; London: W B Saunders.
162. Walker J, Quirke P. Biology and genetics of colorectal cancer. Eur. J. Cancer 2001;37:S163-S172.
163. Samowitz WS, Holden JA, Curtin K, et al. Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. Am. J. Pathol. 2001;158:1517-1524.
164. Jen J, Wu L, Sidaransky D. An overview on the isolation and analysis of circulating tumor DNA in plasma and serum. Ann. NY Acad. Sci. 2000;906:8-12.
165. Anker P. Quantitative aspects of plasma/serum DNA in cancer patients. Ann. NY Acad. Sci. 2000;906:5-7.
166. Stroun M, Maurice P, Vasioukhin V, et al. The origin and mechanism of circulating DNA. Ann. NY Acad. Sci. 2000;906:161-168.
167. JCostello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG island methylation has non-random and tumor-type-specifc patterns. Nat. Genet. 2000;24:132-138.
168. Ahlquist DA, Shuber AP. Stool screening for colorectal cancer: Evolution from occult blood to molecular markers. Clin. Chim. Acta. 2002;315:157-168.
169. Wharton RQ, Jonas SK, Glover C, et al. Increased detection of circulating tumor cells in the bloodof colorectal carcinoma patients using two reverse transcription-PCR assays and multiple blood samples. Clin. Cancer Res. 1999;5:4158-4163.
170. Sanchez-Cespedes M, Esteller M, Hibi K, et al. Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence. Clin. Cancer Res. 1999;5:2450-2454.
171. Leung WK, To KF, Man EPS, et al. Qualitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am. J. Gastroenterol 2005;100:2274-2279.
172. Grady WM, Rajput A, Lutterbaugh JD, Markowitz DS. Detection of abberantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 2001;61:900-902.
173. Zou HZ, Yu MB, Wang ZW, et al. Detection of aberrant p16 methylation in serum of colorectal cancer patients. Clin. Cancer Res. 2002;8:188-191.
174. McShane LM, Altman DG, Sauerbrei W, et al. Reporting Recommendation for Tumor Marker Prognostic Studies (REMARK). J. Natl. Cancer Inst. 2005;97:1180-1184.
175. McShane LM, Altman DG, Sauerberi W, et al. Reporting recommendations for tumor MARKer prognostic studies (REMARK). Eur. J. Cancer 2005;41:1690-1696.
176. Egger M, Smith GD. Meta-analysis: Potentials and promise. Br. Med. J. 1997;315:1371-1374.
177. Aebi S, Fink D, Gordon R, et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin. Cancer Res. 1997;3:1763-1767.
178. Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int. J. Cancer 2003;106:66-73.
179. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA 1998;95:6870-6875.
180. Bearzatto A, Szadkowski M, Macpherson P, et al. Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents. Cancer Res. 2000;60:3262-3270.
181. Kim HC, Kim CN, Yu CS, et al. Methylation of the hMLH1 and hMSH2 promoter in early-onset sporadic colorectal carcinoma with microsatellite instability. Int. J. Colorectal. Dis. 2003;18:196-202.
182. Kantharidis P, El-Osta A, deSilva M, et al. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin. Cancer Res. 1997;3:2025-2032.
183. van Rijnsoever M, Grieu F, Elsaleh H, et al. Charecterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut. 2002;51:797-802.
184. Van Rijnsoever M, Elsaleh H, Joseph, D, et al. CpG island methylator phenotype is an independent predictor of survival benefits from 5-fluorouracil in stage III colorectal cancer. Clin. Cancer Res. 2003;9:2898-2903.
185. Arnold CN, Goel A, Boland R. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int. J. Cancer 2003;106:66-73.
186. Nakagawa H, Chadwick RB, Peltomaki P, et al. Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc. Natl. Acad. Sci. USA 2001;98:591-596.
187. Bird AP. Use of restriction enzymes to study eukaryotic DNA methylation. II. The symmetry of methylated sites supports semi-conservative copying of the methylation pattern. J. Mol. Biol. 1977;118:49-60.
188. Gonzalgo ML, Liang G, Spruck III CH, et al. Identification of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. Cancer Res. 1997;57:594-499.
189. McClelland M. The effect of sequence specific DNA methylation restricted endonuclease cleavage. Nucleic. Acids. Res. 1981;9:5859-5866.
190. Toyota M, Ho C, Ahuja N, et al. Identification of differentially methylated sequences in colorectal cancer by nethylated CpG island amplification. Cancer Res. 1999;59:2307-2312.
191. Huang TH, Perry MR, Laux DE. Methylation profiling of CpG islands in human breast cancer cells. Hum. Mol. Genet 1999;8:459-470.
192. Shi H, Yan PS, Chen CM, et al. Expressed CpG island sequence tag microarray for dual screening of DNA hypermethylation and gene silencing in cancer cells. Cancer Res. 2002;62:3214-3220.
193. Hayashizaki Y, Hirotsune S, Okazaki Y, et al. Restriction landmark genomic scanning method and its various applications. Electrophoresis 1993;14:251-258.
194. Schatz P, Distler J, Berlin K, Schuster M. Novel methof for high throughput DNA methylation marker evaluation using PnA-probe library hybridization and MALDI-TOF detection. Nucleic. Acids. Res. 2006;34:e59.
195. Benhattar J, Clément G. Methylation-sensitive single-strand conformation analysis: A rapid method to screen for and analyze DNA methylation. Methods. Mol. Biol. 2004;287:181-193.
196. Liang G, Gonzales FA, Jones PA, et al. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res. 2002;62:961-966.
197. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet. 2002;31:141-149.
198. Hatada I, Kato A, Morita S, et al. A microarray-based method for detecting methylated loci. J. Hum. Genet. 2002;47:448-451.
199. Li J, Protopopov A, Wang F, et al. NotI subtraction and NotI-specific microarrays to detect copy number and methylation changes in whole genomes. Proc. Natl. Acad. Sci. USA 2002;99:10724-10729.
200. Frigola J, Ribas M, Risques RA, et al. Methylome profiling of cancer cells by amplification of inter-methylated sites (AIMS). Nucleic. Acids Res. 2002;30:e28.
201. Brock GJ, Huang TH, Chen CM, et al. A novel technique for the identification of CpG islands exhibiting altered methylation patterns (ICEAMP). Nucleic. Acids Res. 2001;29:E123.
202. Tompa R, McCallum CM, Delrow J, et al. Genome-wide profiling of DNA methylation reveals transosons targets of CHROMOMETHYLASE3. Curr. Biol. 2002;121:65-68.
203. Gitan RS, Shi H, Chen CM, et al. Methylation-specific oligonucleotide microarray: A new potential for high-throughput methylation analysis. Genome. Res. 2002;12:158-164.
204. Adorjan P, Distler J, Lipscher E, et al. Tumor class prediction and discovery by microarray-based DNA methylation analysis. Nucleic. Acids Res. 2002;30:e21.
205. Balog RP, de Souza YE, Tang HM, et al. Parallel assessment of CpG methylation by two-color hybridization with oligonucleotide array. Anal. Biochem. 2002;309:301-310.
206. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 1996;93:9821-9826.
207. Hong, KM, Yang SH, Guo M, et al. Semiautomatic detection of DNA methylation at CpG islands. BioTechniques 2005;38:354-358.
208. Rand K, Qu W, Ho T, et al. Conversion-specific detection of DNA methylation using real-time polymerase chain reaction. ConLight-MSP to avoid false positives. Methods 2002;27:114-120.
209. Eads CA, Danenberg KD, Kawakami K, et al. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res. 1999;59:2302-2306.
210. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: A high-throughput assay to measure DNA methylation. Nucleic. Acids Res. 2000;28:E32.
211. Zeschni KM, Böhringer S, Price, et al. A novel real-time PCR assay
212. Cottrell SE, Distler J, Goodman NS, et al. A real time PCR assay for DNA methylation using methylation-specific blockers. Nucleic. Acids Res. 2004;32:e10.
213. Thomassin H, Kress C, Grange T. MethylQuant: A sensitive method for quantifying methylation of specific cytosines within the genome. Nucleic. Acids Res. 2004;32:e168.
214. Akey DT, Akey JM, Zhnag K, Jin L. Assaying DNA methylation based on high-throughput melting curve approaches. Genomics 2002;80:376-384.
215. Gonzalgo ML, Jones PA. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension. Ms-SNuPE. Nucleic. Acids Res. 1997;25:2529-2531.
216. Matin MM, Baumer A, Homby DP. An analytical method for the detection of methylation differences at specific chromosomal loci using primer extension and ion pair reverse phase HPLC. Hum. Mutat. 2002;20:305-311.
217. Uhlmann K, Brickmann A, Toliat MR, et al. Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis. Electrophoresis 2002;23:4072-4079.
218. Tost J, Schatz P, Schuster M, et al. Analysis and accurate quantification of CpG methylation by MALDI mass spectrometry. Nucleic. Acids. Res. 2003;31:e50.
219. Xiong Z, Laird PW. COBRA: A sensitive and quantitative DNA methylation assay. Nucleic. Acids Res. 1997;25:2532-2534.
220. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. USA 1992;89:1827-1831.
221. Betz B, Florl A, Seifert HH, et al. Denaturing high-performance liquid chromatography. SHPLC as a reliable high-throughput prescreening method for aberrant promoter methylation in cancer. Hum. Mutat. 2004;23:612-620.
222. Baumer A, Wiedemann U, Hergersberg M, Schinzel A. A novel MSP/DHPLC method for the investigation of the methylation status of imprinted genes enables the molecular detection of low cell mosaicism. Hum. Mutat. 2001;17:423-430.
223. Schafz P, Dietrich D, Schuster M. Rapid analysis of CpG methylation patterns using RNase T1 cleavage and MALDI-TOF. Nucleic. Acids. Res. 2004;32:e167.
224. Tost J, Schatz P, Schuster M, et al. Analysis and accurate quantification of CpG methylation by MALDI mass spectrometry. Nucleic. Acids Res. 2003;31:e50.
225. Tost J, Dunker J, Gut IG. Analysis and quantification of multiple methylation variable positions in CpG islands by pyrosequencing. BioTechnique 2003;35:152-156.
226. Tost J, Eladalaui H, Gut IG. Serial pyrosequencing for quantitative DNA methylation analysis. BioTechniques 2006;40:721-726.
227. Shaw RJ, Akufo-Tetteh EK, Risk JM, et al. Methylation enrichment pyrosequencing combining the specificity of MSP with validation by pyrosequencing. Nucleic. Acids Res. 2006;34:e78.
228. Worm J, Aggerholm A, Guldberg P. In-tube DNA methylation profiling by fluorescent melting curve analysis. Clin. Chem. 2001;47:1183-1189.
229. Wu J, Smith LT, Plass C, Huang THM. Chip-chip comes of age for genome-wide functional analysis. Cancer Res. 2006;66:6899-6902.
230. Matarazzo MR, Lembo F, Angrisano T, et al. In vivo analysis of DNA methylation patterns recognized by specific proteins: Coupling ChIP and bisulfite analysis. BioTechnique 2004;37:666-673.
231. Kondo Y, Chen L, Yan PS, et al. Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation. Proc. Natl. Acad. Sci. USA 2004;101:7398-7403.
232. Oberley MI, Tsao J, Lau P, Farnham PJ. High-throughput screening of chromatin immunoprecipitation using CpG-island microarrays. Methods Enzymol. 2004;376:315-334.
233. Yang AS, Estécio RH, Doshi K, et al. A single method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic. Acids Res. 2004;32:E38.
234. Dahl C, Guldberg P. DNA methylation analysis techniques. Biogerontology 2003;4:233-250.
235. Brena RM, Auer H, Kornacker K, et al. Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform. Nucleic. Acids Res. 2006;34:e17.
236. Liu ZJ, Maekawa M. Polymerase chain reaction based methods of DNA methylation analysis. Anal. Biochem. 2003;317:259-265.
237. Shi H, Maier S, Ninnrich l, et al. Oligonucleotide based microarray for DNA methylation analysis: Principles and applications. J. Cell. Biochem. 2003;88:138-143.
238. van Steensel B, Henikoff S. Epigenetic profiling using microarrays. BioTechniques 2003;35:346-357.
239. Ahmed FE. Artificial neural networks for diagnosis and survival prediction in colon cancer. Molec. Cancer 2005;4:29.
240. Ahmed FE. Colorectal cancer: Prevelance, screening, gene expression andmutation, and risk factors and assessment. Environ. Carcino. Ecotox. Revs. 2003;C21:65-131.
241. Ahmed FE. Effect of diet, life style, and other environmental/ chemopreventive factors on colorectal cancer development and assessments of the risks. Environ. Carcino. Ecotox. Revs. 2004;C22:91-147.
242. Li E, Beard C, Forster AC, Bestor TH, Jaenish R. DNA methylation, genomic imprinting and mammalian development. Cols. Spring Harbor. Symp. Quant. Viol. 1992;58:297-305.
243. Ahmed FE, Vos P, iJames S, et al. Transcriptomic molecular markers for screening human colon cancer in stool and tissue. Cancer Genom. Proteom. 2007;4:1-20.